论文部分内容阅读
目的旨在初步评估新型动脉微栓滤器一体化氧合器(ALF-MO)在先心病患儿体外循环(CPB)中应用的临床效果。方法自2012年10月至2013年7月,共有44名行心脏直视手术的患儿纳入本研究,其中试验组(n=22)患儿采用含ALF-MO的CPB管路;对照组(n=22)患儿采用常规独立动脉微栓滤器(ALF)的CPB管路。对比研究两组患儿在围CPB期的悬浮红细胞(PRBC)用量、血气变化和术后早期的恢复情况。结果试验组患儿CPB中的预充量明显少于对照组预充量(P<0.05)。试验组总PRBC用量显著少于对照组(P<0.001)。试验组患儿在CPB30min时的血红蛋白浓度均明显高于对照组(P<0.05),代谢缓冲碱BE值明显高于对照组(P<0.05);其他时点的各项血气指标两组间均无显著性差异(P>0.05)。两组患儿气管插管时间和ICU停留时间比较无统计学差异(P>0.05),术后均无死亡,无中枢视神经系统并发症发生。结论应用ALF-MO在先心病患儿CPB中应用是安全可靠的,同时为实施节约用血和改善患儿预后起到积极的推进作用。
The aim was to initially assess the clinical efficacy of a novel arterial micro-plug filter integrated oxygenator (ALF-MO) for cardiopulmonary bypass (CPB) in children with congenital heart disease. METHODS: From October 2012 to July 2013, a total of 44 children undergoing open-heart surgery were enrolled in this study. CPB tubes containing ALF-MO were used in the study group (n = 22) n = 22) Children underwent CPB with a conventional independent arterial micro-plug filter (ALF). To compare the amount of suspended erythrocyte (PRBC), blood gas changes and early postoperative recovery in two groups of children with CPB. Results The pretreatment volume of CPB in experimental group was significantly less than that in control group (P <0.05). The total amount of PRBC in the experimental group was significantly less than that in the control group (P <0.001). The hemoglobin concentration of children in experimental group was significantly higher than that of control group (P <0.05), and the BE value of metabolic buffer base was significantly higher than that of control group (P <0.05). The other indexes No significant difference (P> 0.05). There was no significant difference in tracheal intubation time and ICU stay between the two groups (P> 0.05). No death occurred after operation and no central optic neuropathy occurred. Conclusion The application of ALF-MO in children with congenital heart disease is safe and reliable. At the same time, it plays a positive role in promoting blood-conserving and improving children’s prognosis.